PTCL

12 registered clinical trials studyying PTCL — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL NCT07493330	Ruijin Hospital	Phase 1 / Phase 2
Not Yet Recruiting	SHR2554 as Maintenance Therapy in Patients With Peripheral T-cell Lymphoma NCT07347288	The First Affiliated Hospital with Nanjing Medical University	Phase 2
Active Not Recruiting	Toripalimab Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma NCT06492629	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Phase 2
Recruiting	A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide. NCT05967949	The First Affiliated Hospital with Nanjing Medical University	—
Unknown	Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL NCT05238064	Fudan University	Phase 1 / Phase 2
Active Not Recruiting	Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL NCT03240211	University of Virginia	Phase 1
Unknown	A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma NCT04705090	Shanghai YingLi Pharmaceutical Co. Ltd.	Phase 2
Recruiting	Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL NCT04747236	University of Virginia	Phase 2
Completed	Phase 1 Study of PTX-100 in Patients With Advanced Malignancies With PTCL Expansion Cohort NCT03900442	Prescient Therapeutics, Ltd.	Phase 1
Unknown	GDPE/CEOPE Compared With CEOPE for Newly Diagnosed Patients With PTCL NCT03884205	Shandong Provincial Hospital	—
Completed	Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms NCT03493451	BeiGene	Phase 2
Withdrawn	Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL NCT02757248	Anne Beaven, MD	Phase 1